Overview

An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Status:
Withdrawn

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.

Phase:

Phase 2

Details

Lead Sponsor:

Chimerix

Treatments:

Antiviral Agents
Brincidofovir